vs
Side-by-side financial comparison of Oportun Financial Corp (OPRT) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $209.6M, roughly 1.2× Varex Imaging Corp). Oportun Financial Corp runs the higher net margin — 1.4% vs 1.1%, a 0.3% gap on every dollar of revenue. On growth, Varex Imaging Corp posted the faster year-over-year revenue change (4.9% vs -1.3%). Over the past eight quarters, Varex Imaging Corp's revenue compounded faster (0.8% CAGR vs -0.5%).
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
OPRT vs VREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.7M | $209.6M |
| Net Profit | $3.4M | $2.3M |
| Gross Margin | — | 33.3% |
| Operating Margin | 2.6% | 7.3% |
| Net Margin | 1.4% | 1.1% |
| Revenue YoY | -1.3% | 4.9% |
| Net Profit YoY | -61.0% | 866.7% |
| EPS (diluted) | $0.07 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $209.6M | ||
| Q4 25 | $247.7M | $228.9M | ||
| Q3 25 | $238.7M | $203.0M | ||
| Q2 25 | $234.3M | $212.9M | ||
| Q1 25 | $235.9M | $199.8M | ||
| Q4 24 | $250.9M | — | ||
| Q3 24 | $250.0M | $205.7M | ||
| Q2 24 | $250.4M | $209.1M |
| Q1 26 | — | $2.3M | ||
| Q4 25 | $3.4M | $12.2M | ||
| Q3 25 | $5.2M | $-89.1M | ||
| Q2 25 | $6.9M | $6.9M | ||
| Q1 25 | $9.8M | $-300.0K | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $-30.0M | $-51.1M | ||
| Q2 24 | $-31.0M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 34.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 32.6% | ||
| Q2 24 | — | 32.0% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 2.6% | 8.6% | ||
| Q3 25 | 6.0% | -39.8% | ||
| Q2 25 | 4.3% | 10.4% | ||
| Q1 25 | 5.6% | 5.6% | ||
| Q4 24 | 89.6% | — | ||
| Q3 24 | -15.8% | 5.3% | ||
| Q2 24 | -19.6% | 4.4% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | 1.4% | 5.3% | ||
| Q3 25 | 2.2% | -43.9% | ||
| Q2 25 | 2.9% | 3.2% | ||
| Q1 25 | 4.1% | -0.2% | ||
| Q4 24 | 200.1% | — | ||
| Q3 24 | -12.0% | -24.8% | ||
| Q2 24 | -12.4% | 0.7% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $0.07 | $0.29 | ||
| Q3 25 | $0.11 | $-2.15 | ||
| Q2 25 | $0.14 | $0.17 | ||
| Q1 25 | $0.21 | $-0.01 | ||
| Q4 24 | $0.26 | — | ||
| Q3 24 | $-0.75 | $-1.25 | ||
| Q2 24 | $-0.78 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.5M | $125.6M |
| Total DebtLower is stronger | — | $367.6M |
| Stockholders' EquityBook value | $390.1M | $476.9M |
| Total Assets | $3.3B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $125.6M | ||
| Q4 25 | $105.5M | $155.1M | ||
| Q3 25 | $104.6M | $152.6M | ||
| Q2 25 | $96.8M | $223.0M | ||
| Q1 25 | $78.5M | $212.6M | ||
| Q4 24 | $60.0M | — | ||
| Q3 24 | $71.8M | $200.5M | ||
| Q2 24 | $72.9M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $390.1M | $472.6M | ||
| Q3 25 | $383.9M | $455.3M | ||
| Q2 25 | $376.0M | $549.7M | ||
| Q1 25 | $366.1M | $540.2M | ||
| Q4 24 | $353.8M | — | ||
| Q3 24 | $327.6M | $529.1M | ||
| Q2 24 | $354.1M | $581.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $3.3B | $1.1B | ||
| Q3 25 | $3.2B | $1.1B | ||
| Q2 25 | $3.2B | $1.4B | ||
| Q1 25 | $3.2B | $1.3B | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.3B | $1.2B | ||
| Q2 24 | $3.3B | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $413.4M | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -12.8% |
| Capex IntensityCapex / Revenue | — | 5.1% |
| Cash ConversionOCF / Net Profit | 121.45× | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $413.4M | $7.9M | ||
| Q3 25 | $99.0M | $7.7M | ||
| Q2 25 | $104.5M | $16.6M | ||
| Q1 25 | $101.0M | $9.5M | ||
| Q4 24 | $393.5M | — | ||
| Q3 24 | $108.5M | $25.9M | ||
| Q2 24 | $107.7M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $19.9M | ||
| Q2 24 | — | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 9.7% | ||
| Q2 24 | — | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | — | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | 121.45× | 0.65× | ||
| Q3 25 | 19.05× | — | ||
| Q2 25 | 15.20× | 2.41× | ||
| Q1 25 | 10.34× | — | ||
| Q4 24 | 45.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPRT
Segment breakdown not available.
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
